Cargando…

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?

Detalles Bibliográficos
Autor principal:	Lee, Hye Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Liver Cancer Association 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035738/ https://www.ncbi.nlm.nih.gov/pubmed/37383406 http://dx.doi.org/10.17998/jlc.2022.09.20

Ejemplares similares

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma
por: Sohn, Won
Publicado: (2021)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
por: Kwan, Byung Soo, et al.
Publicado: (2021)

Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
por: Ahn, Young-Hwan, et al.
Publicado: (2022)

Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals
por: Mercan-Stanciu, Adriana, et al.
Publicado: (2022)

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
por: Kamp, William M., et al.
Publicado: (2019)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2021)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus
por: Mawatari, Seiichi, et al.
Publicado: (2022)

Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals
por: Li, Shihui, et al.
Publicado: (2022)

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
por: Ahn, Young-Hwan, et al.
Publicado: (2021)

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
por: Syed, Taseen, et al.
Publicado: (2018)

The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?
por: Strazzulla, Alessio, et al.
Publicado: (2016)

Two Cases of Hepatocellular Carcinoma Occurring Immediately after Direct-acting Antiviral Agents against Hepatitis C Virus
por: Nishijima, Norihiro, et al.
Publicado: (2018)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
por: Kishta, Sara, et al.
Publicado: (2020)

Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
por: Matsumae, Takayuki, et al.
Publicado: (2023)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus
por: Ghanem, Samar Ebrahim, et al.
Publicado: (2021)

Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD
por: Roche, Meaghan, et al.
Publicado: (2019)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
por: Kuftinec, Gabriela, et al.
Publicado: (2018)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals
por: Tabu, Kazuaki, et al.
Publicado: (2020)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
por: Frazzoni, Leonardo, et al.
Publicado: (2021)

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
por: Kuromatsu, Ryoko, et al.
Publicado: (2022)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dfotelv8q9m76anc4fpuaaiskq